Alpha Teknova opened lower at $8.41, compared with its previous close of $8.62. In the last trading session, the stock traded between $8.04 and $8.64. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Alpha Teknova is now worth
$ 33.35
Resulting in a loss of
$ 66.65 (66.65%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-0.33 (-3.79%)
Day High
$8.64
Day Low
$8.04
Day Open
$8.41
Prev Close
$8.62
Volume
3,07,333
1W Return
12.91%
1M Return
-4.61%
3M Return
17.85%
6M Return
117.66%
1Y Return
69.24%
Fundamentals
Market Cap ($ Mn)
522
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-16.00%
EPS (TTM)
$-0.06
Investment Returns
1 Week
12.91%
1 Month
-4.61%
3 Months
17.85%
6 Months
117.66%
9 Months
293.03%
Financials
Quarterly
All values in $ Mn
10.3
Jun 25
10.5
Sep 25
10.0
Dec 25
11.1
Mar 26
12.2
Jun 26
12.7
Sep 26
Updates
5Nov
Alpha Teknova Q3FY26 Results: Revenue rises 22% to record $12.2 million
Revenue rose 22% YoY to a record $12.2 million, driven by custom product demand. Gross margin expanded 400 bps to 38.0%, aided by inventory absorption and scale. Clinical Solutions revenue surged 86% YoY to $3.2 million on larger GMP orders. Company raised FY26 revenue guidance to $46–$48 million after completing a $46 million equity raise.
8 days ago
22Oct
Teknova Q3FY26 Results: Earnings release set for November 4, 2026
Alpha Teknova Inc. will report Q3FY26 results on November 4, 2026. Conference call scheduled for 6:00 pm ET on the same day. Webcast replay available two hours post-event.
22 days ago
21Oct
Alpha Teknova prices $40 million offering at $5.00 per share
Alpha Teknova priced its public offering of 8 million shares at $5.00 per share. Gross proceeds from the deal total $40 million before underwriting discounts. Shares fell 22.87% in after-hours trading following the pricing announcement. Preliminary Q3 revenue estimates range between $12.5 million and $12.7 million.
22 days ago
21Oct
Alpha Teknova Q3FY26 Results: Revenue up 19-21% YoY, EBITDA loss narrows
Revenue estimated at $12.5 million to $12.7 million, reflecting 19% to 21% YoY growth. Gross margin expanded by 500 to 700 basis points YoY, driven by top-line growth. Adjusted EBITDA loss narrowed by at least 25% YoY due to cost discipline. Cash and short-term investments stood at $16.6 million as of September 30, 2026.
23 days ago
3Oct
Teknova, Pluristyx file FDA DMF for PluriFreeze cryopreservation system
Alpha Teknova and Pluristyx completed a Type II Drug Master File for PluriFreeze. The DMF supports IND and BLA applications for cell therapy developers. PluriFreeze PF10 contains 10% DMSO and maintains stability for two years at 2-8 °C. Teknova serves as the exclusive manufacturer and distributor in the US and Canada.
1mo ago
17Sep
Jefferies initiates Alpha Teknova coverage with Buy, $9 target
Jefferies initiates coverage on Alpha Teknova (NASDAQ: TKNO). Analyst Matthew Stanton assigns a Buy rating. Price target is set at $9.
